184 related articles for article (PubMed ID: 38630388)
41. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
42. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
43. Clinical Features and Prognosis of Diffuse Midline Glioma: A Series of 24 Cases.
Jang SW; Song SW; Kim YH; Cho YH; Hong SH; Kim JH; Ra YS; Chong S
Brain Tumor Res Treat; 2022 Oct; 10(4):255-264. PubMed ID: 36347640
[TBL] [Abstract][Full Text] [Related]
44. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
[TBL] [Abstract][Full Text] [Related]
45. H3 G34-mutant high-grade glioma.
Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
[TBL] [Abstract][Full Text] [Related]
46. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
47. Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.
Watanabe G; Wong JM; Estes B; Khan MF; Ogasawara C; Umana GE; Martin AR; Bloch O; Palmisciano P
J Neurooncol; 2024 Feb; 166(3):379-394. PubMed ID: 38342826
[TBL] [Abstract][Full Text] [Related]
48. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma.
Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM
J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807
[TBL] [Abstract][Full Text] [Related]
49. Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria.
Ryckman JM; Appiah AK; Lyden E; Verma V; Zhang C
Am J Clin Oncol; 2019 Apr; 42(4):391-398. PubMed ID: 30768441
[TBL] [Abstract][Full Text] [Related]
50. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
51. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
52. MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.
Rodriguez D; Calmon R; Aliaga ES; Warren D; Warmuth-Metz M; Jones C; Mackay A; Varlet P; Le Deley MC; Hargrave D; Cañete A; Massimino M; Azizi AA; Saran F; Zahlmann G; Garcia J; Vassal G; Grill J; Peet A; Dineen RA; Morgan PS; Jaspan T
Radiology; 2022 Jul; 304(1):174-182. PubMed ID: 35412366
[TBL] [Abstract][Full Text] [Related]
53. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract][Full Text] [Related]
54. The role of radiation and chemotherapy in adult patients with high-grade brainstem gliomas: results from the National Cancer Database.
Kerezoudis P; Goyal A; Lu VM; Alvi MA; Bydon M; Kizilbash SH; Burns TC
J Neurooncol; 2020 Jan; 146(2):303-310. PubMed ID: 31873874
[TBL] [Abstract][Full Text] [Related]
55. Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas.
Dorfer C; Czech T; Gojo J; Hosmann A; Peyrl A; Azizi AA; Kasprian G; Dieckmann K; Filbin MG; Haberler C; Roessler K; Slavc I
Acta Neurochir (Wien); 2021 Jul; 163(7):2025-2035. PubMed ID: 33090244
[TBL] [Abstract][Full Text] [Related]
56. Midline Gliomas: A Retrospective Study from a Cancer Center in the Middle East.
Al Sharie S; Abu Laban D; Nazzal J; Iqneibi S; Ghnaimat S; Al-Ani A; Al-Hussaini M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760513
[TBL] [Abstract][Full Text] [Related]
57. Clinical and Genomic Characteristics of Adult Diffuse Midline Glioma.
Park C; Kim TM; Bae JM; Yun H; Kim JW; Choi SH; Lee ST; Lee JH; Park SH; Park CK
Cancer Res Treat; 2021 Apr; 53(2):389-398. PubMed ID: 33171023
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Adjuvant Radiation Therapy Alone and Chemotherapy Alone in Surgically Resected Low-Grade Gliomas: Survival Analyses of 2253 Cases from the National Cancer Data Base.
Wu J; Neale N; Huang Y; Bai HX; Li X; Zhang Z; Karakousis G; Huang R; Zhang PJ; Tang L; Xiao B; Yang L
World Neurosurg; 2018 Apr; 112():e812-e822. PubMed ID: 29409888
[TBL] [Abstract][Full Text] [Related]
59. Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high-risk grade 2 glioma: An analysis of the National Cancer Data Base.
Jhaveri J; Liu Y; Chowdhary M; Buchwald ZS; Gillespie TW; Olson JJ; Voloschin AD; Eaton BR; Shu HG; Crocker IR; Curran WJ; Patel KR
Cancer; 2018 Mar; 124(6):1169-1178. PubMed ID: 29205287
[TBL] [Abstract][Full Text] [Related]
60. Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.
Li Q; Dong F; Jiang B; Zhang M
Front Oncol; 2021; 11():646267. PubMed ID: 34109112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
